FATE

Fate Therapeutics
$2.43
+$0.02 (+0.83%)Jul 27, 2026
2.4FairMoatMint rating

MoatMint rates Fate Therapeutics (FATE) 2.4 out of 10, a research rating of the company's quality, value, growth, momentum and financial health. Its quality rating is 2.7 out of 10.

Key metrics

The numbers that frame FATE today
Market cap
$283.24M
P/E (TTM)
-2.2
EV / FCF
-2.9
Gross margin
100%
EV / Sales
49.1
ROIC
-39.9%
Div yield
0%
Debt / equity
0.4
52wk Low
$0.91
52wk High
$3.23

FATE stock rating

How FATE scores on quality, value, growth, momentum and financial health
2.4out of 10
Fair overallFair business, expensive priceTop 76% of ~5,000 US stocks
QualityFair2.7/10
GrowthPoor0.9/10
MomentumGreat8.9/10
ValuePoor0.9/10
Financial HealthPoor1.7/10

Growth

Revenue and earnings trend for FATE
RevenueNet income
See the full growth breakdown

Revenue and earnings trends, margins and the multi-year trajectory - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Cash flow & returns

Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture

Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.

Create a free account
Free foreverNo card required
Already a member? Log in

Insider trading

Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade

See who is buying and selling, how much, and when - updated as new filings land.

Create a free account
Free foreverNo card required
Already a member? Log in

Frequently asked questions

Plain-English answers about FATE
Is Fate Therapeutics a good buy?
Hold. Fate Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Fate Therapeutics is selling at a very high price.
What is the market capitalization of FATE?
Fate Therapeutics's market capitalization is $283.24M.
What is the P/E ratio for FATE stock?
Fate Therapeutics's current P/E ratio is -2.2.
What is the 52-week high for FATE stock?
The 52-week high for Fate Therapeutics is $3.23. The current close of $2.43 is 24.8% below that high.
What is the 52-week low for FATE stock?
The 52-week low for Fate Therapeutics is $0.91. The current close of $2.43 is 167% above that low.
Does FATE stock pay dividends?
Fate Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for FATE?
Fate Therapeutics's Debt / Equity ratio is 0.43.